symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ALPN,10.2,1.182163,300070,501855300,0,4.82-14.92,0.2,"Alpine Immune Sciences, Inc.",USD,0001626199,US02083G1004,02083G100,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.alpineimmunesciences.com,"Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",Dr. Mitchell H. Gold M.D.,Healthcare,US,126,206 788 4545,188 East Blaine Street,Seattle,WA,98102,1.63544,9.26544,https://financialmodelingprep.com/image-stock/ALPN.png,2015-06-17,False,False,True,False,False
